Ahmed A Hamed, Zeinab G Khalil
The antibiotic pipeline is in crisis, even though microbial natural products, account for most approved antibacterial drugs and retain vast, untapped biosynthetic potential. Genuinely new scaffolds are rare because discovery remains constrained to a narrow set of cultivable taxa and expressed biosynthetic gene clusters, while most microbial chemistry persists as "dark matter" in uncultured organisms and silent clusters. Each bottleneck is both a discovery and a biotechnology challenge: a predicted cluster must be expressed, its product isolated, and its biosynthesis engineered to workable titres before any hit can realistically progress. This review links the major obstacles in the contemporary pipeline including limited ecological sampling, silent and cryptic clusters, access to uncultured bacteria, inefficient metabolome mining, weak genome-metabolome integration, and incomplete target identification, to the technologies best suited to address them, drawing on recent case studies of integrated workflows rather than single-platform approaches. By evaluating these strategies for both discovery power and bioprocess tractability, we outline a practical framework for turning microbial dark matter into producible, mechanistically understood antibiotic leads.